An analysis of US Medicare beneficiaries showed that patients with T2D were significantly more likely to receive an SGLT-2i or a GLP-1 RA if these agents were included on less expensive formulary tiers (tiers 1–3) [71]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.